Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Allergan to Pay Medytox for Neurotoxin Licensing
Motley Fool
Friday, September 27, 2013 - 8:25am
tags:
Allergan, Medytox, neurotoxins
The Billion Dollar Molecule
Seeking Alpha
Friday, September 27, 2013 - 8:24am
tags:
GSK, Pfizer, Roche, Puma Biotechnology, neratinib, breast cancer
How AbbVie Plans to Survive After Humira
Motley Fool
Friday, September 27, 2013 - 8:20am
tags:
AbbVie, Humira, Ablynx, ALX-0061
3 Companies at the Cutting Edge of Diabetes Research
Motley Fool
Friday, September 27, 2013 - 8:18am
tags:
diabetes, Eli Lilly, Merck, MannKind
J&J warns doctors Doxil shortage will hit next month
Fierce Pharma
Thursday, September 26, 2013 - 2:53pm
tags:
Doxil, ovarian cancer, JNJ, drug shortages, Sun Pharma
How Well Does Pharma Disclose Political Spending?
Pharmalot
Thursday, September 26, 2013 - 2:52pm
tags:
political spending
Could This Popular Diabetes Treatment Also Treat Alzheimer's Disease?
Motley Fool
Thursday, September 26, 2013 - 2:50pm
tags:
Alzheimer's disease, diabetes, Novo Nordisk, Victoza
3 Key Points From Sarepta's Eteplirsen Study Update (And They're Positive)
TheStreet.com
Thursday, September 26, 2013 - 10:35am
tags:
Sarepta, eteplirsen, Genentech, GSK, Duchenne Muscular Dystrophy
Boxed Warning of HBV Risk Added to Rituxan, Arezerra
Med Page Today
Thursday, September 26, 2013 - 10:28am
tags:
warnings, Rituxan, hepatitis B, Arezerra, ofatamumab, rituximab
Sanofi cholesterol drug touted as potential $3 billion blockbuster
Reuters
Thursday, September 26, 2013 - 10:25am
tags:
Sanofi, Regeneron, alirocumab, PCSK9 inhibitors
FDA distributes $3.5M to spark pediatric device development
Fierce Medical Devices
Thursday, September 26, 2013 - 10:22am
tags:
FDA, pediatrics, devices
Did PacBio Just Sorta Sell Itself To Roche?
Seeking Alpha
Thursday, September 26, 2013 - 10:01am
tags:
Pacific Biosciences, Roche
Verastem Initiates Phase 2 Trial of Defactinib in Lung Cancer
Yahoo
Thursday, September 26, 2013 - 9:48am
tags:
Defactinib, Verastem, non-small cell lung cancer
Galena: Acquisition Prospects And Exciting Catalysts
Seeking Alpha
Thursday, September 26, 2013 - 9:12am
tags:
Galena Biopharma, stock offering, M&A, AstraZeneca
Stryker, Medtronic lose preemption bids in OP-1, Calstrux and Infuse lawsuit
Mass Device
Thursday, September 26, 2013 - 8:55am
tags:
Stryker, Medtronic, Calstrux, infuse, bone growth proteins, devices
Sanofi starts work on $95 mln Algerian plant, biggest in Africa
Reuters
Thursday, September 26, 2013 - 8:52am
tags:
Africa, Sanofi, drug manufacturing
VIVUS' Hopes Tied to Qsymia
Yahoo/Zacks
Thursday, September 26, 2013 - 8:51am
tags:
Vivus, Qsymia, obesity
Some Speculative Biotechs Making Major Moves
Seeking Alpha
Thursday, September 26, 2013 - 8:50am
tags:
Dynavax, Omeros, Pacific Biosciences
Ex-CEO of Amgen, Kevin Sharer, on Leadership
Harvard Business Review
Thursday, September 26, 2013 - 8:21am
tags:
Amgen, Leadership, Pharma CEOs, Kevin Sharer
Exelixis achieves enrollment target for phase 3 trial of cabozantinib
Yahoo/Fly on the Wall
Thursday, September 26, 2013 - 8:19am
tags:
Exelixis, cabozantinib, metastatic castration-resistant prostate cancer

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.